Vinci Pharmaceuticals Raises Over $8M in Series A Funding

Vinci Pharmaceuticals, an Avon-by-the-Sea, NJ-based provider of a sustained drug delivery platform for retinal diseases, has raised over $8 million in a Series A funding round, bringing the total amount to over $16.5 million.

The round was led by Dynagrow Capital, with participation from MintPharma Capital.

The company will use the funding to support manufacturing, testing, and release activities for its EPIPLANT VCI-002 product, along with preparations for a Phase 1/2a clinical study planned for 2027.

What is Vinci Pharmaceuticals?

Vinci Pharmaceuticals develops drug delivery technology designed to treat retinal diseases. Its EPIPLANT platform uses a bioerodible episcleral implant to deliver medication gradually to retinal tissues.

Read More:Health Care Startup Outro Secures $7M in Funding

Existing treatments for retinal diseases may require injections directly into the eye or face challenges in maintaining effective drug concentrations in retinal tissues. Vincis technology aims to provide sustained drug delivery, and reduce the treatment burden for patients.

The platform is designed to accommodate different active pharmaceutical ingredients, potentially supporting treatments for multiple retinal diseases. The company has received multiple patents covering it's proprietary EPIPLANT technology and completed preliminary preclinical testing.

How Much Funding Has Vinci Pharmaceuticals Raised?

Vinci Pharmaceuticals has raised over $8 million in its latest Series A funding round, bringing its total funding to more than $16.5 million.

The latest round was led by Dynagrow Capital, with participation from MintPharma Capital.

Who Invested in Vinci Pharmaceuticals’ Series A?

The Series A funding round was led by Dynagrow Capital.

MintPharma Capital also participated in the round.

Why the Funding Matters

Vinci Pharmaceuticals will use the new funding to support good manufacturing practice (GMP) manufacturing, testing, and release activities for its EPIPLANT VCI-002 product.

The funds will also support preparations for the company's planned Phase 1/2a clinical study in 2027.

Who founded Vinci Pharmaceuticals?

Vinci Pharmaceuticals was founded in 2019 by Philip Gioia.

The company is headquartered in Avon-by-the-Sea, New Jersey, and focuses on developing ophthalmic treatments using its proprietary sustained drug delivery platform.

"We are grateful for the support and confidence of our investors and board, who recognize the potential of our EPIPLANT™ delivery system to transform the treatment of sight-threatening diseases and address unmet needs in the field," said Philip A. Gioia, Co-founder, Chairman and Chief Executive Officer of Vinci Pharmaceuticals.

"EPIPLANT™ delivers targeted drug levels to the macula, making it a more desirable option for treating certain ophthalmic diseases of the retina compared to intravitreal injections, the current standard of care," said Richard Lindstrom, MD, of Minnesota Eye Consultants.

Market and Business Growth

Vinci Pharmaceuticals has received multiple patents covering its EPIPLANT technology and completed preliminary preclinical testing.

The platform is designed to deliver small-molecule drugs gradually to retinal tissues through an episcleral implant. This approach could support the development of treatments for multiple retinal diseases.

The company is preparing to advance its VCI-002 product toward clinical evaluation.

What Happens Next?

Vinci Pharmaceuticals plans to support manufacturing and testing activities for EPIPLANT VCI-002 and prepare for a Phase 1/2a clinical study in 2027.

The company will continue developing its sustained drug delivery platform for retinal diseases.

Read More:Fintech Startup Peppermint Raises $4.7M in Seed Funding